ImmunityBio, Inc.
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
Funding history
About ImmunityBio, Inc.
How much funding has ImmunityBio, Inc. raised?
ImmunityBio, Inc. has raised $470.0M in total funding.
Where is ImmunityBio, Inc. headquartered?
ImmunityBio, Inc. is headquartered in San Diego, CA.
What does ImmunityBio, Inc. do?
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
What problem does ImmunityBio, Inc. solve?
Cancer and infectious diseases remain difficult to durably treat, and existing approaches like CAR-T or checkpoint inhibitors have limits.
What's ImmunityBio, Inc.'s solution?
ImmunityBio develops immunotherapies that activate both innate and adaptive immune responses (NK cells, T cells, macrophages, dendritic cells) to attack disease and build lasting immunological memory, with the goal of reducing reliance on high-dose chemotherapy.
What makes ImmunityBio, Inc. different?
They describe a 'triangle offense' immunotherapy approach and a goal of outperforming existing treatments like CAR-T or checkpoint inhibitors, framed as 'Smart Therapies for Difficult Diseases.'
What makes ImmunityBio, Inc. notable?
Founded by Dr. Patrick Soon-Shiong, the billionaire biotech entrepreneur and surgeon who also owns the Los Angeles Times.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.